Shota Obata

Shota Obata

Auto-generated profile, based on publicly available information

Shota Obata

Department of Medicine, Division of Nephrology Stanford University School of Medicine Palo Alto USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
AKArjun Lalit Kalaria
Arjun Lalit Kalaria
TYTakayuki Yamada
Takayuki Yamada
MKMichele Klein-Fedyshin
Michele Klein-Fedyshin
SOShota Obata
Shota Obata
MCMassiel Cruz-Peralta
Massiel Cruz-Peralta
RMRajil B Mehta
Rajil B Mehta
Introduction: Subclinical rejection (SCR) refers to the presence of acute rejection without accompanying kidney allograft dysfunction. The impact of SCR on long-term graft survival remains a subject of ongoing debate. Methods and analysis: We will perform a systematic search of databases including MEDLINE, Embase and Cochrane Central, from January 1995 to November 2023. We will include English-language studies involving adult kidney transplant patients who investigated SCR. We will exclude studies focused on ‘for-cause’ biopsies. Both title, abstract screening and full-text screening will be performed by two or more reviewers. The primary outcome of this study will be death-censored allograft loss. The secondary outcome will include development of subsequent rejection. For time-dependent outcomes, we will prioritise HRs and the 95% CIs. In cases where HRs are unavailable, we will calculate risk ratios based on the recorded events. The risk of bias will be assessed using the Cochrane Collaboration’s revised tool for assessing the risk of bias in randomised trials and the Newcastle-Ottawa scale for cohort studies. We will employ a random effects model. We will evaluate heterogeneity using the I 2 variable. We will assess publication bias by funnel plots, Begg and Mazumdar test, and Egger’s test. Ethics and dissemination: Ethics approval does not apply as no original data will be collected. The results will be disseminated through peer-reviewed publications and conference presentations. PROSPERO registration number: CRD42023463536.

8 April 2026 in Clinical Transplantation
Verified
Journal Article
Open access
TYTakayuki Yamada
Takayuki Yamada
SOShota Obata
Shota Obata
AKArjun Kalaria
Arjun Kalaria
AAAbiha Abdullah
Abiha Abdullah
BPBryce Parrish
Bryce Parrish
MMMichele Molinari
Michele Molinari
Background: The prognostic significance of subclinical rejection (SCR) and borderline rejection (BLR) detected on surveillance kidney allograft biopsies remains uncertain. Methods: We performed a systematic review and meta‐analysis of studies enrolling adult kidney transplant (KT) recipients undergoing protocol biopsies. The primary outcome was death‐censored graft loss (DCGL); the secondary outcome was subsequent rejection. Random‐effects models, sensitivity analyses, and meta‐regression were used. Results: Fifteen studies (5428 recipients) were included. SCR was associated with a higher risk of DCGL (RR 2.22; 95% CI 1.67–2.95) and subsequent rejection (RR 3.09; 95% CI 2.34–4.09), with low heterogeneity. Both T cell–mediated rejection (RR 1.82; 95% CI 1.28–2.61) and antibody‐mediated rejection (ABMR) (RR 3.35; 95% CI 2.11–5.33) were associated with increased DCGL. BLR was associated with increased DCGL (RR 2.40; 95% CI 1.67–3.46) and subsequent rejection (RR 2.79; 95% CI 2.10–3.69). Findings were robust across sensitivity analyses, including contemporary Banff‐era definitions. Conclusions: SCR and BLR are associated with inferior long‐term graft outcomes. These findings underscore their prognostic significance and warrant prospective studies to determine optimal management strategies.

18 December 2024 in Transplant Infectious Disease
Verified
Journal Article
Closed access
SOShota Obata
Shota Obata
SHSumi Hidaka
Sumi Hidaka
SKShuzo Kobayashi
Shuzo Kobayashi